The Art of Stopping: Why Deprescribing Is the Clinical Skill Medicine Has Long Neglected

There is a particular asymmetry embedded in the culture of American medicine. Initiating a medication is framed as action—a clinical decision that signals attentiveness, competence, and care. Discontinuing one, by contrast, is too often experienced as retreat, uncertainty, or even negligence. This asymmetry is not merely philosophical. It has measurable consequences for patients, particularly those managing multiple chronic conditions across multiple prescribers in a fragmented healthcare system that rarely pauses to ask: does this patient still need everything they are taking?

The answer, increasingly, is no. And the failure to act on that answer has a name: deprescribing failure. It is quiet, cumulative, and underrecognized—but the evidence linking it to preventable harm is both substantial and growing.

Polypharmacy and the Accumulation Problem

Polypharmacy—broadly defined as the concurrent use of five or more medications—affects an estimated 42 percent of Americans over the age of 65, with rates climbing sharply among those managing three or more chronic conditions. In long-term care settings, that figure is considerably higher. Medications accumulate through a process that is entirely logical at the individual prescribing level: a cardiologist adds a beta-blocker, a rheumatologist initiates a corticosteroid, a primary care physician prescribes a proton pump inhibitor to manage the gastrointestinal effects. Each decision, viewed in isolation, follows evidence-based guidelines. Viewed together, they represent a pharmacological burden that no single guideline was designed to address.

The clinical consequences are well-documented. Drug-drug interactions increase exponentially with each additional agent. Adverse drug events account for approximately 700,000 emergency department visits annually in the United States, with older adults bearing a disproportionate share of that burden. Falls, cognitive impairment, renal deterioration, and hospitalizations traceable to medication burden are not rare complications—they are predictable outcomes of a system that has optimized for adding without building equivalent infrastructure for subtracting.

Why Clinicians Do Not Stop

Understanding deprescribing failure requires confronting the specific barriers that prevent clinicians from discontinuing medications that have become unnecessary, inappropriate, or actively harmful. These barriers operate at multiple levels simultaneously.

Psychological inertia is among the most powerful. A medication initiated during a prior clinical encounter carries implicit endorsement from the prescribing clinician, and overriding that endorsement—even one's own—requires a degree of cognitive effort that routine clinical workflows rarely support. The status quo exerts a gravitational pull that is difficult to overcome in a fifteen-minute appointment.

Liability concerns compound the problem. Clinicians who discontinue a medication and observe a subsequent adverse event may face professional and legal scrutiny in ways that clinicians who maintain an existing regimen typically do not, even when the maintenance decision was the more harmful one. This asymmetry in accountability discourages proactive deprescribing and reinforces the cultural preference for pharmacological addition over subtraction.

Fragmented care creates structural obstacles that are independent of individual clinician intent. In a system where specialists operate in relative isolation from one another, no single clinician may have full visibility into a patient's complete medication list. Primary care physicians often inherit regimens initiated by specialists who are no longer involved in the patient's care, with limited documentation of the original rationale or intended duration. Discontinuing under these conditions requires clinical courage and time that many practitioners simply do not have.

Patient and caregiver resistance also plays a meaningful role. Many patients have been taking certain medications for years and associate them with stability, even when the clinical evidence for continued benefit has eroded. Proposing discontinuation can be perceived as abandonment or as a signal that the clinician has given up. Navigating that perception requires communication skills that medical education has historically underemphasized.

The Evidence Base for Deprescribing

What is often missing from clinical conversations about medication discontinuation is recognition that deprescribing is not a clinical improvisation—it is an evidence-based discipline with a growing body of research to support it. Tools such as the Beers Criteria, the STOPP/START criteria, and the Medication Appropriateness Index provide structured frameworks for identifying medications that are potentially inappropriate in older adults. These instruments were not designed as administrative checklists; they represent synthesized clinical evidence about which pharmacological agents carry risk profiles that are likely to outweigh benefit in specific patient populations.

Randomized controlled trials examining systematic deprescribing interventions have demonstrated reductions in falls, hospitalizations, and all-cause mortality in older adults. A landmark Australian trial found that a structured deprescribing protocol in nursing home residents was associated with a 45 percent reduction in mortality over a twelve-month period—a finding that, if replicated in a pharmaceutical context, would generate significant clinical enthusiasm. That it has not produced equivalent urgency in prescribing culture speaks directly to the asymmetry described above.

Pharmacist-led medication reviews, increasingly integrated into primary care practices and accountable care organizations across the United States, represent one of the more promising implementation models. When pharmacists are embedded in clinical teams with authority to recommend deprescribing in collaboration with prescribing physicians, both the rate of medication discontinuation and patient safety outcomes improve. This interdisciplinary model positions deprescribing not as a unilateral physician decision but as a coordinated clinical process—one that distributes the cognitive burden and creates shared accountability.

Reframing Deprescribing as Clinical Competence

The deeper challenge is cultural. American medical education has historically framed pharmacotherapy as a problem-solving tool—something clinicians do when patients present with conditions requiring intervention. Deprescribing requires inverting that framework: recognizing that the intervention itself may have become the problem, and that stopping requires the same clinical rigor, evidence synthesis, and patient communication as starting.

Medical schools and residency programs have begun to incorporate deprescribing curricula into their training, and professional organizations including the American Geriatrics Society have issued guidance supporting systematic medication review as a standard of care for older adults. These are meaningful steps. But they will remain insufficient until the clinical culture treats a well-executed deprescribing decision with the same professional recognition accorded to a well-chosen new therapy.

For AAPTS members, the implications are direct. Advancing patient care through scientific excellence means applying the same evidentiary standards to discontinuation that we apply to initiation. It means building practice systems that support regular medication review, investing in interdisciplinary models that distribute deprescribing competency across care teams, and advocating for liability frameworks that do not penalize clinicians who act on evidence to reduce pharmacological burden.

Conclusion

The medications we prescribe carry a responsibility that does not end at the point of initiation. Every drug on a patient's regimen represents an ongoing clinical decision—one that should be revisited with the same rigor applied when it was first made. Deprescribing failure is not an inevitable byproduct of complex medicine. It is a correctable gap in clinical practice, and correcting it is among the most consequential patient safety investments the medical community can make. The science supports action. What remains is the will to stop.